Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 in relapsed/refractory indolent B‑cell lymphomas (Phase IIa/IIb)
CTR20210169Phase 2Completed
- Sponsor
- Bibet Pharmaceutical
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifupinostat in follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL) and 2 more, sponsored by Bibet Pharmaceutical. Primary endpoint: Objective response rate (ORR). Started Feb 2021; status: completed.
02
Drugs
ifupinostat
03
Conditions
follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20210169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210169.